{"id":450056,"date":"2021-03-03T16:18:24","date_gmt":"2021-03-03T21:18:24","guid":{"rendered":"http:\/\/www.marketnewsdesk.com\/?p=450056"},"modified":"2021-03-03T16:18:24","modified_gmt":"2021-03-03T21:18:24","slug":"transparency-notification-received-from-the-capital-group","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/transparency-notification-received-from-the-capital-group\/","title":{"rendered":"Transparency notification received from The Capital Group"},"content":{"rendered":"
\n

\n Mechelen, Belgium; 3 March 2021; 22.15 CET; regulated information \u2013 Galapagos NV (Euronext & NASDAQ: GLPG) received a new transparency notification from The Capital Group Companies, Inc.<\/strong>
\n \n <\/p>\n

Pursuant to Belgian transparency legislation1<\/sup>, Galapagos received a transparency notification on 26 February 2021 from The Capital Group Companies, Inc., who notified that it holds 9.91% of the current 65,411,767 outstanding Galapagos shares. The Capital Group Companies, Inc. thus crossed below the 10% threshold of Galapagos\u2019 voting rights by disposing of voting securities on 22 February\u00a02021. The full transparency notice is available on the Galapagos website.<\/p>\n

\n About Capital Group<\/strong>
\n
Capital Group controls Capital Bank & Trust Company and Capital Research & Management Company through its direct subsidiary Capital Group International, Inc. (\u201cCGII\u201d), controls four CGII investment management companies (Capital International, Inc.; Capital International Limited, Capital International S\u00e0rl; and Capital International K.K.), which all together hold 6,483,973 of Galapagos\u2019 voting rights, consisting of ordinary shares, which represents 9.91%.<\/p>\n

\n About Galapagos<\/strong>
\n
Galapagos NV discovers and develops small molecule medicines with novel modes of action, several of which show promising patient results and are currently in late-stage development in multiple diseases. Our pipeline comprises Phase 3 through to discovery programs in inflammation, fibrosis, and other indications. Our ambition is to become a leading global biopharmaceutical company focused on the discovery, development and commercialization of innovative medicines. More information at www.glpg.com<\/u>.<\/p>\n

\n Contacts
<\/strong>
\n
\n Investors:<\/strong>
\n
Elizabeth Goodwin
VP Investor Relations
+1 781 460 1784<\/p>\n

Sofie Van Gijsel
Senior Director Investor Relations
+32 485 19 14 15
ir@glpg.com<\/u><\/a><\/p>\n

\n Media:<\/strong>
\n
Carmen Vroonen
Global Head Communications & Public Affairs
+32 473 824 874<\/p>\n

Anna Gibbins
Senior Director Therapeutic Areas Communications
+44 7717 801900
communications@glpg.com<\/u><\/a><\/p>\n

\n

\n <\/p>\n

\n 1<\/sup> \u00a0Belgian Act of 2 May 2007 on the disclosure of major shareholdings in issuers whose shares are admitted to trading on a regulated market<\/p>\n<\/p>\n

\n

\n Attachment<\/strong>\n <\/p>\n